Eskiler, Gamze GüneyYurdacan, Beste2024-11-262024-11-262019-08-011095-6670https://doi.org/10.1002/jbt.22338https://hdl.handle.net/11452/48445The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor-positive breast and prostate cancer (BC and PC), respectively. The antiproliferative and apoptotic effects of Tam or Enz alone and in combination with UA on MCF7 and LNCaP cancer cells were detected. The results of the WST-1 assay indicated that UA was a promising anticancer compound that significantly enhanced the effectiveness of hormone therapy drugs compared with each drug alone (combination index < 1). In addition, the combination of UA with Tam or Enz remarkably induced more cell cycle arrest at the G0/G1 phase and apoptosis than only drug-treated cells (P < 0.01). Consequently, our findings suggest that the combination of UA with Tam or Enz may be a potential therapeutic approach for the treatment of BC and PC and further studies are required to exploit the potential mechanisms of synergistic effects.eninfo:eu-repo/semantics/closedAccessEndocrine therapyResistanceMechanismsApoptosisCompoundToxicityAgentsCombination treatmentEnzalutamideHormone receptor-positive cancersTamoxifenUsnic acidScience & technologyLife sciences & biomedicineBiochemistry & molecular biologyToxicologyArticle00048062520000233810.1002/jbt.22338